276 related articles for article (PubMed ID: 34911862)
1. Advances in therapeutic targets-related study on systemic lupus erythematosus.
Wang X; Zhang Q; Luo S; Zhang H; Lu Q; Long H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Nov; 46(11):1267-1275. PubMed ID: 34911862
[TBL] [Abstract][Full Text] [Related]
2. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
3. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.
Vincent FB; Saulep-Easton D; Figgett WA; Fairfax KA; Mackay F
Cytokine Growth Factor Rev; 2013 Jun; 24(3):203-15. PubMed ID: 23684423
[TBL] [Abstract][Full Text] [Related]
4. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
5. B cells targeting therapy in the management of systemic lupus erythematosus.
Lee WS; Amengual O
Immunol Med; 2020 Mar; 43(1):16-35. PubMed ID: 32107989
[TBL] [Abstract][Full Text] [Related]
6. B-cell-targeted therapy for systemic lupus erythematosus: an update.
Ding C; Foote S; Jones G
BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
[TBL] [Abstract][Full Text] [Related]
7. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
Fan Y; Gao D; Zhang Z
Drugs Today (Barc); 2022 Jan; 58(1):23-32. PubMed ID: 35107091
[TBL] [Abstract][Full Text] [Related]
8. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
9. From mechanism to therapies in systemic lupus erythematosus.
Paley MA; Strand V; Kim AH
Curr Opin Rheumatol; 2017 Mar; 29(2):178-186. PubMed ID: 28118202
[TBL] [Abstract][Full Text] [Related]
10. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
Yap DYH; Chan TM
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
[TBL] [Abstract][Full Text] [Related]
11. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
12. Lupus: novel therapies in clinical development.
Chugh PK
Eur J Intern Med; 2012 Apr; 23(3):212-8. PubMed ID: 22385876
[TBL] [Abstract][Full Text] [Related]
13. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
14. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
Vincent FB; Morand EF; Mackay F
Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
[TBL] [Abstract][Full Text] [Related]
15. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
16. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians.
Sanchez-Niño MD; Ortiz A
Nephrol Dial Transplant; 2015 Mar; 30(3):394-400. PubMed ID: 24914092
[TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematosus.
Tanaka Y
Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101814. PubMed ID: 36702700
[TBL] [Abstract][Full Text] [Related]
18. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
Steiger S; Ehreiser L; Anders J; Anders HJ
Front Immunol; 2022; 13():999704. PubMed ID: 36211360
[TBL] [Abstract][Full Text] [Related]
19. New and future therapies: Changes in the therapeutic armamentarium for SLE.
Askanase A; Khalili L; Tang W; Mertz P; Scherlinger M; Sebbag E; Chasset F; Felten R; Arnaud L
Best Pract Res Clin Rheumatol; 2023 Dec; 37(4):101865. PubMed ID: 37633826
[TBL] [Abstract][Full Text] [Related]
20. Belimumab therapy in systemic lupus erythematosus.
Zouali M; Uy EA
BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
